Hepatitis C virus infection in patients with HIV-1: Epidemiology, natural history and management

Expert Review of Gastroenterology and Hepatology

Volumn 8, Issue 3, 2014, Pages 247-266

  Kang, Wen ^a,b   Tong, Hsin I ^a   Sun, Yongtao ^b   Lu, Yuanan ^a  

^a UNIVERSITY OF HAWAII   (United States)

^b FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

antiretroviral agents; direct acting anti HCV agents; drug interaction; drug therapy; epidemiology; orthotropic liver transplantation; pathogenesis

Indexed keywords

ANTI-RETROVIRAL AGENTS; COMORBIDITY; DISEASE MANAGEMENT; DISEASE PROGRESSION; END STAGE LIVER DISEASE; HEPACIVIRUS; HEPATITIS C; HIV INFECTIONS; HIV-1; HUMANS; INTERFERON-ALPHA; LIVER TRANSPLANTATION; POLYETHYLENE GLYCOLS; RECOMBINANT PROTEINS; RIBAVIRIN; TREATMENT OUTCOME;

EID: 84894158961     PISSN: 17474124     EISSN: 17474132     Source Type: Journal    
DOI: 10.1586/17474124.2014.876357     Document Type: Review

References (168)

1. Joint United Nations Programme on HIV/AIDS. World AIDS Day Report. 2011. Available from: www.unaids.org/en/media/unaids/contentassets/documents/ unaidspublication/2011/JC2216- WorldAIDSday-report-2011-en.pdf
2. Lavanchy D. Evolving epidemiology of hepatitis C virus. Clin Microbiol Infect 2011;17(2):107-15
3. Merchante N, Merino E, Lopez-Aldeguer J, et al. Increasing incidence of hepatocellular carcinoma in HIV-infected patients in Spain. Clin Infect Dis 2013;56(1):143-50
4. Weber R, Ruppik M, Rickenbach M, et al. Decreasing mortality and changing patterns of causes of death in the Swiss HIV Cohort Study. HIV Med 2013;14(4):195-207
5. Limketkai BN, Mehta SH, Sutcliffe CG, et al. Relationship of liver disease stage and antiviral therapy with liver-related events and death in adults coinfected with HIV/HCV. JAMA 2012;308(4):370-8
6. Sulkowski MS, Mehta SH, Torbenson MS, et al. Rapid fibrosis progression among HIV/hepatitis C virus-co-infected adults. AIDS 2007;21(16):2209-16
7. Carton JA, Collazos J, De La Fuente B, Asensi V. Course of liver fibrosis in HIV-hepatitis C virus-coinfected patients depending on the response to hepatitis C therapy. AIDS Res Hum Retroviruses 2013; 29(2):215-22
8. Laguno M, Cifuentes C, Murillas J, et al. Randomized trial comparing pegylated interferon alpha-2b versus pegylated interferon alpha-2a, both plus ribavirin, to treat chronic hepatitis C in human immunodeficiency virus patients. Hepatology 2009;49(1):22-31
9. Carrat F, Bani-Sadr F, Pol S, et al. Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial. JAMA 2004; 292(23):2839-48
10. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services; Available from: http://aidsinfo.nih. gov/contentfiles/lvguidelines/AdultandAdolescentGL.pdf
11. Nelson PK, Mathers BM, Cowie B, et al. Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews. Lancet 2011; 378(9791):571-83
12. Rockstroh JK, Mocroft A, Soriano V, et al. Influence of hepatitis C virus infection on HIV-1 disease progression and response to highly active antiretroviral therapy. J Infect Dis 2005;192(6):992-1002
13. Zhou J, Dore GJ, Zhang F, et al. Hepatitis B and C virus co-infection in The TREAT Asia HIV Observational Database. J Gastroenterol Hepatol 2007;22(9):1510-18
14. Petoumenos K, Ringland C; Australian HIVOD. Antiretroviral treatment change among HIV, hepatitis B virus and hepatitis C virus co-infected patients in the Australian HIV Observational Database. HIV Med 2005;6(3):155-63
15. Backus LI, Boothroyd D, Deyton LR. HIV, hepatitis C and HIV/hepatitis C virus co-infection in vulnerable populations. AIDS 2005;19(Suppl 3):S13-19
16. Braitstein P, Justice A, Bangsberg DR, et al. Hepatitis C co-infection is independently associated with decreased adherence to antiretroviral therapy in a population-based HIV cohort. AIDS 2006;20(3):323-31
17. Speers S, Klevens RM, Vonderwahl C, et al. Electronic matching of HIV/AIDS and hepatitis C surveillance registries in three states. Public Health Rep 2011;126(3): 344-8
18. Taylor LE, Holubar M, Wu K, et al. Incident hepatitis C virus infection among US HIV-infected men enrolled in clinical trials. Clin Infect Dis 2011;52(6):812-18
19. Perez Cachafeiro S, Caro-Murillo AM, Berenguer J, et al. Association of Patients' Geographic Origins with Viral Hepatitis Co-infection Patterns, Spain. Emerg Infect Dis 2011;17(6):1116-19
20. Labarga P, Soriano V, Caruz A, et al. Association between IL28B gene polymorphisms and plasma HCV-RNA levels in HIV/HCV-co-infected patients. AIDS 2011;25(6):761-6
21. Hernando V, Perez-Cachafeiro S, Lewden C, et al. All-cause and liver-related mortality in HIV positive subjects compared to the general population: differences by HCV co-infection. J Hepatol 2012;57(4):743-51
22. Laufer N, Quarleri J, Bouzas MB, et al. Hepatitis B virus, hepatitis C virus and HIV co-infection among people living with HIV/AIDS in Buenos Aires, Argentina. Sex Transm Dis 2010;37(5):342-3
23. Sun HY, Chang SY, Yang ZY, et al. Recent hepatitis C virus infections in HIV-infected patients in Taiwan: incidence and risk factors. J Clin Microbiol 2012;50(3):781-7
24. Anggorowati N, Yano Y, Heriyanto DS, et al. Clinical and virological characteristics of hepatitis B or C virus co-infection with HIV in Indonesian patients. J Med Virol 2012;84(6):857-65
25. Mohammadi M, Talei G, Sheikhian A, et al. Survey of both hepatitis B virus (HBsAg) and hepatitis C virus (HCV-Ab) co-infection among HIV positive patients. Virol J 2009;6:202
26. Zhao YS, Su SI, Lv CX, et al. Seroprevalence of hepatitis C, hepatitis B virus and syphilis in HIV-1 infected patients in Shandong, China. Int J STD AIDS 2012;23(9):639-43
27. Bharti AR, Letendre SL, Wolfson T, et al. Clinical variables identify seronegative HCV co-infection in HIV-infected individuals. J Clin Virol 2011;52(4):328-32
28. Thomson EC, Nastouli E, Main J, et al. Delayed anti-HCV antibody response in HIV-positive men acutely infected with HCV. AIDS 2009;23(1):89-93
29. Thomson EC, Fleming VM, Main J, et al. Predicting spontaneous clearance of acute hepatitis C virus in a large cohort of HIV-1-infected men. Gut 2011;60(6): 837-45
30. European AIDS Treatment Network (NEAT) Acute Hepatitis C Infection Consensus Panel. Acute hepatitis C in HIV-infected individuals: recommendations from the European AIDS Treatment Network (NEAT) consensus conference. AIDS 2011;25(4):399-409.
31. Orsetti E, Staffolani S, Gesuita R, et al. Changing characteristics and risk factors of patients with and without incident HCV infection among HIV-infected individuals. Infection 2013;41(5):987-90
32. Soriano V, Mocroft A, Rockstroh J, et al. Spontaneous viral clearance, viral load, and genotype distribution of hepatitis C virus (HCV) in HIV-infected patients with anti-HCV antibodies in Europe. J Infect Dis 2008;198(9):1337-44
33. Sofian M, Aghakhani A, Banifazl M, et al. Viral hepatitis and HIV infection among injection drug users in a central iranian city. J Addict Med 2012;6(4):292-6
34. Garten RJ, Zhang J, Lai S, et al. Coinfection with HIV and hepatitis C virus among injection drug users in southern China. Clin Infect Dis 2005;41(Suppl 1): S18-24
35. Zhou YH, Yao ZH, Liu FL, et al. High prevalence of HIV, HCV, HBV and co-infection and associated risk factors among injecting drug users in Yunnan province, China. PLoS ONE 2012;7(8): e42937
36. Tanimoto T, Nguyen HC, Ishizaki A, et al. Multiple routes of hepatitis C virus transmission among injection drug users in Hai Phong. Northern Vietnam. J Med Virol 2010;82(8):1355-63
37. Bottieau E, Apers L, Van Esbroeck M, et al. Hepatitis C virus infection in HIV-infected men who have sex with men: sustained rising incidence in Antwerp. Belgium, 2001-2009. Euro Surveill 2010;15(39): 19673
38. Tseng YT, Sun HY, Chang SY, et al. Seroprevalence of hepatitis virus infection in men who have sex with men aged 18-40 years in Taiwan. J Formos Med Assoc 2012;111(8):431-8
39. Jin F, Prestage GP, Matthews G, et al. Prevalence, incidence and risk factors for hepatitis C in homosexual men: data from two cohorts of HIV-negative and HIV-positive men in Sydney, Australia. Sex Transm Infect 2010;86(1):25-8
40. Ruan Y, Qin G, Yin L, et al. Incidence of HIV, hepatitis C and hepatitis B viruses among injection drug users in southwestern China: a 3-year follow-up study. AIDS 2007;21(Suppl 8):S39-46
41. Miller CL, Wood E, Spittal PM, et al. The future face of co-infection: prevalence and incidence of HIV and hepatitis C virus coinfection among young injection drug users. J Acquir Immune Defic Syndr 2004;36(2): 743-9
42. Judd A, Hickman M, Jones S, et al. Incidence of hepatitis C virus and HIV among new injecting drug users in London: prospective cohort study. BMJ 2005; 330(7481):24-5
43. Naggie S, Sulkowski MS. Management of patients coinfected with HCV and HIV: a close look at the role for direct-acting antivirals. Gastroenterology 2012;142(6): 1324-34.e1323
44. Hagan H, Thiede H, Des Jarlais DC. HIV/hepatitis C virus co-infection in drug users: risk behavior and prevention. AIDS 2005; 19(Suppl 3):S199-207
45. Van Den Berg CH, Smit C, Bakker M, et al. Major decline of hepatitis C virus incidence rate over two decades in a cohort of drug users. Eur J Epidemiol 2007;22(3): 183-93
46. CDC. Sexual transmission of hepatitis C virus among HIV-infected men who have sex with men - New York City, 2005-2010. MMWR Morb Mortal Wkly Rep 2011; 60(28):945-50
47. Van Der Helm JJ, Prins M, Del Amo J, et al. The hepatitis C epidemic among HIV-positive MSM: incidence estimates from 1990 to 2007. AIDS 2011;25(8): 1083-91.
48. Yaphe S, Bozinoff N, Kyle R, et al. Incidence of acute hepatitis C virus infection among men who have sex with men with and without HIV infection: a systematic review. Sex Transm Infect 2012;88(7):558-64
49. Van De Laar T, Pybus O, Bruisten S, et al. Evidence of a large, international network of HCV transmission in HIV-positive men who have sex with men. Gastroenterology 2009;136(5):1609-17 . This is a phylogenetic study that revealed a large international network of HCV transmission among HIVpositive men who have sex with men in Europe.
50. Van De Laar TJ, Van Der Bij AK, Prins M, et al. Increase in HCV incidence among men who have sex with men in Amsterdam most likely caused by sexual transmission. J Infect Dis 2007;196(2):230-8
51. Diamond C, Thiede H, Perdue T, et al. Viral hepatitis among young men who have sex with men: prevalence of infection, risk behaviors, and vaccination. Sex Transm Dis 2003;30(5):425-32
52. Alary M, Joly JR, Vincelette J, et al. Lack of evidence of sexual transmission of hepatitis C virus in a prospective cohort study of men who have sex with men. Am J Public Health 2005;95(3):502-5
53. Jin F, Prestage GP, Kippax SC, et al. Prevalence and risk factors of hepatitis C in HIV-negative homosexual men in Sydney, Australia. Aust NZ J Public Health 2005; 29(6):536-9
54. Hao C, Yan H, Yang H, et al. The incidence of syphilis, HIV and HCV and associated factors in a cohort of men who have sex with men in Nanjing. China. Sex Transm Infect 2011;87(3):199-201
55. Briat A, Dulioust E, Galimand J, et al. Hepatitis C virus in the semen of men coinfected with HIV-1: prevalence and origin. AIDS 2005;19(16):1827-35
56. Marx MA, Murugavel KG, Tarwater PM, et al. Association of hepatitis C virus infection with sexual exposure in southern India. Clin Infect Dis 2003;37(4):514-20
57. Danta M, Rodger AJ. Transmission of HCV in HIV-positive populations. Curr Opin HIV AIDS 2011;6(6):451-8
58. Schmidt AJ, Rockstroh JK, Vogel M, et al. Trouble with bleeding. risk factors for acute hepatitis C among HIV-positive gay men from Germany - a case-control study. PLoS ONE 2011;6(3):e17781
59. Matthews GV, Hellard M, Haber P, et al. Characteristics and treatment outcomes among HIV-infected individuals in the Australian trial in acute hepatitis C. Clin Infect Dis 2009;48(5):650-8
60. Obermeier M, Ingiliz P, Weitner L, et al. Acute hepatitis C in persons infected with the human immunodeficiency virus (HIV). The "real-life setting" proves the concept. Eur J Med Res 2011;16(5):237-42
61. Larsen C, Chaix ML, Le Strat Y, et al. Gaining greater insight into HCV emergence in HIV-infected men who have sex with men. The HEPAIG Study. PLoS ONE 2011;6(12):e29322
62. Bolcic F, Laufer N, Trinchero J, et al. A clustering phenomenon among HCV-1a strains among patients coinfected with HIV from Buenos Aires, Argentina. J Med Virol 2012;84(4):570-81
63. Graham CS, Baden LR, Yu E, et al. Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection. A meta-analysis. Clin Infect Dis 2001;33(4):562-9
64. Klein MB, Rollet KC, Saeed S, et al. HIV and hepatitis C virus co-infection in Canada: challenges and opportunities for reducing preventable morbidity and mortality. HIV Med 2013;14(1):10-20
65. Rockstroh JK, Peters L, Grint D, et al. Does hepatitis C viremia or genotype predict the risk of mortality in individuals co-infected with HIV? J Hepatol 2013; 59(2):213-20
66. Piroth L, Larsen C, Binquet C, et al. Treatment of acute hepatitis C in human immunodeficiency virus-infected patients: the HEPAIG study. Hepatology 2010;52(6): 1915-21
67. Kamal SM. Acute hepatitis C: a systematic review. Am J Gastroenterol 2008;103(5): 1283-97.quiz 1298
68. Nattermann J, Timm J, Nischalke HD, et al. The predictive value of IL28B gene polymorphism for spontaneous clearance in a single source outbreak cohort is limited in patients carrying the CCR5Delta32 mutation. J Hepatol 2011; 55(6):1201-6
69. Lunge VR, Da Rocha DB, Beria JU, et al. IL28B polymorphism associated with spontaneous clearance of hepatitis C infection in a Southern Brazilian HIV type 1 population. AIDS Res Hum Retroviruses 2012;28(2):215-19
70. Van Den Berg CH, Grady BP, Schinkel J, et al. Female sex and IL28B, a synergism for spontaneous viral clearance in hepatitis C virus (HCV) seroconverters from a community-based cohort. PLoS ONE 2011; 6(11):e27555
71. Harfouch S, Guiguet M, Valantin MA, et al. Lack of TGF-beta production by hepatitis C virus-specific T cells during HCV acute phase is associated with HCV clearance in HIV co-infection. J Hepatol 2012;56(6):1259-68
72. Harcourt G, Gomperts E, Donfield S, Klenerman P. Diminished frequency of hepatitis C virus specific interferon gamma secreting CD4+ T cells in human immunodeficiency virus/hepatitis C virus coinfected patients. Gut 2006;55(10): 1484-7
73. Flynn JK, Dore GJ, Matthews G, et al. Impaired hepatitis C virus (HCV)-specific interferon-gamma responses in individuals with HIV who acquire HCV infection. correlation with CD4+ T-Cell Counts. J Infect Dis 2012;206(10):1568-76
74. Schnuriger A, Dominguez S, Guiguet M, et al. Acute hepatitis C in HIV-infected patients: rare spontaneous clearance correlates with weak memory CD4 T-cell responses to hepatitis C virus. AIDS 2009; 23(16):2079-89
75. Danta M, Semmo N, Fabris P, et al. Impact of HIV on host-virus interactions during early hepatitis C virus infection. J Infect Dis 2008;197(11):1558-66
76. Reiberger T, Aberle JH, Kundi M, et al. IP-10 correlates with hepatitis C viral load, hepatic inflammation and fibrosis and predicts hepatitis C virus relapse or non-response in HIV-HCV co-infection. Antivir Ther 2008;13(8):969-76
77. Kim AY, Chung RT. Co-infection with HIV-1 and HCV - a one-two punch. Gastroenterology 2009;137(3):795-814
78. Montes-De-Oca M, Blanco MJ, Marquez M, et al. Haemodynamic derangement in human immunodeficiency virus-infected patients with hepatitis C virus-related cirrhosis: the role of bacterial translocation. Liver Int 2011;31(6):850-8
79. Salmon D, Bani-Sadr F, Loko MA, et al. Insulin resistance is associated with a higher risk of hepatocellular carcinoma in cirrhotic HIV/HCV-co-infected patients. results from ANRS CO13 HEPAVIH. J Hepatol 2012; 56(4):862-8
80. Merchante N, Rivero A, De Los Santos-Gil I, et al. Insulin resistance is associated with liver stiffness in HIV/HCV co-infected patients. Gut 2009; 58(12):1654-60
81. Halfon P, Penaranda G, Carrat F, et al. Influence of insulin resistance on hepatic fibrosis and steatosis in hepatitis C virus (HCV) mono-infected compared with HIV-HCV co-infected patients. Aliment Pharmacol Ther 2009;30(1):61-70
82. Sandler NG, Koh C, Roque A, et al. Host response to translocated microbial products predicts outcomes of patients with HBV or HCV infection. Gastroenterology 2011; 141(4):1220-30.1230.e1221-3
83. Vali B, Jones RB, Sakhdari A, et al. HCV-specific T cells in HCV/HIV co-infection show elevated frequencies of dual Tim-3/PD-1 expression that correlate with liver disease progression. Eur J Immunol 2010;40(9):2493-505
84. Feuth T, Arends JE, Fransen JH, et al. Complementary role of HCV and HIV in T-cell activation and exhaustion in HIV/HCV co-infection. PLoS ONE 2013;8(3): e59302
85. Korner C, Tolksdorf F, Riesner K, et al. Hepatitis C co-infection enhances sensitization of CD4(+) T-cells towards Fas-induced apoptosis in viraemic and HAART-controlled HIV-1-positive patients. Antivir Ther 2011;16(7):1047-55
86. Graham CS, Curry M, He Q, et al. Comparison of HCV-specific intrahepatic CD4+ T cells in HIV/HCV versus HCV. Hepatology 2004;40(1):125-32
87. Morishima C, Shuhart MC, Yoshihara CS, et al. Preservation of intrahepatic hepatitis C virus (HCV)-specific CD4+ T cell responses despite global loss of CD4+ T cells in HCV/HIV co-infection. J Infect Dis 2007; 196(4):577-86
88. Alatrakchi N, Graham CS, He Q, et al. CD8+ cell responses to hepatitis C virus (HCV) in the liver of persons with HCV-HIV co-infection versus HCV monoinfection. J Infect Dis 2005;191(5): 702-9
89. Barrett L, Gallant M, Howley C, et al. Stronger hepatitis C virus-specific CD8+ T-cell responses in HIV co-infection. J Viral Hepat 2011;18(3):170-80
90. Jang JY, Shao RX, Lin W, et al. HIV infection increases HCV-induced hepatocyte apoptosis. J Hepatol 2011;54(4):612-20
91. Tuyama AC, Hong F, Saiman Y, et al. Human immunodeficiency virus (HIV)- 1 infects human hepatic stellate cells and promotes collagen I and monocyte chemoattractant protein-1 expression: implications for the pathogenesis of HIV/hepatitis C virus-induced liver fibrosis. Hepatology 2010;52(2):612-22
92. Bruno R, Galastri S, Sacchi P, et al. gp120 modulates the biology of human hepatic stellate cells: a link between HIV infection and liver fibrogenesis. Gut 2010; 59(4):513-20
93. Hong F, Saiman Y, Si C, et al. X4 human immunodeficiency virus type 1 gp120 promotes human hepatic stellate cell activation and collagen I expression through interactions with CXCR4. PLoS ONE 2012;7(3):e33659
94. Neukam K, Garcia-Rey S, Cifuentes C, et al. HIV-co-infection leads to a modest increase in plasma HCV-RNA load in patients with chronic HCV infection. Antiviral Res 2012;95(3):212-15
95. Vispo E, Fernandez-Montero JV, Labarga P, et al. Low risk of liver toxicity using the most recently approved antiretroviral agents but still increased in HIV-hepatitis C virus coinfected patients. AIDS 2013;27(7): 1187-8
96. Blanco F, Barreiro P, Ryan P, et al. Risk factors for advanced liver fibrosis in HIV-infected individuals: role of antiretroviral drugs and insulin resistance. J Viral Hepat 2011;18(1):11-16
97. Suarez-Zarracina T, Valle-Garay E, Collazos J, et al. Didanosine (ddI) associates with increased liver fibrosis in adult HIV-HCV coinfected patients. J Viral Hepat 2012;19(10):685-93
98. Berenguer J, Bellon JM, Miralles P, et al. Association between exposure to nevirapine and reduced liver fibrosis progression in patients with HIV and hepatitis C virus coinfection. Clin Infect Dis 2008;46(1): 137-43
99. Neukam K, Mira JA, Ruiz-Morales J, et al. Liver toxicity associated with antiretroviral therapy including efavirenz or ritonavir-boosted protease inhibitors in a cohort of HIV/hepatitis C virus co-infected patients. J Antimicrob Chemother 2011; 66(11):2605-14
100. Rallon NI, Soriano V, Restrepo C, et al. HCV-specific T-cell responses in HIV/hepatitis C virus-coinfected patients on highly active antiretroviral therapy are comparable to those observed in hepatitis C virus-monoinfected individuals. J Acquir Immune Defic Syndr 2011;57(1):1-8
101. Chen TY, Ding EL, Seage Iii GR, Kim AY. Meta-analysis. increased mortality associated with hepatitis C in HIV-infected persons is unrelated to HIV disease progression. Clin Infect Dis 2009;49(10):1605-15
102. Sulkowski MS, Moore RD, Mehta SH, et al. Hepatitis C and progression of HIV disease. JAMA 2002;288(2):199-206
103. Collazos J, Carton JA, Asensi V. Evaluation of the possible influence of hepatitis C virus and liver fibrosis on HIV type 1 immunological and virological outcomes. HIV Med 2011;12(5):308-15
104. Kang W, Li Y, Zhuang Y, et al. Dynamic analysis of Th1/Th2 cytokine concentration during antiretroviral therapy of HIV-1/HCV co-infected patients. BMC Infect Dis 2012;12:102
105. Zhuang Y, Wei X, Li Y, et al. HCV coinfection does not alter the frequency of regulatory T cells or CD8+ T cell immune activation in chronically infected HIV+ Chinese subjects. AIDS Res Hum Retroviruses 2012;28(9):1044-51
106. Sajadi MM, Pulijala R, Redfield RR, Talwani R. Chronic immune activation and decreased CD4 cell counts associated with hepatitis C infection in HIV-1 natural viral suppressors. AIDS 2012;26(15):1879-84
107. Berenguer J, Rodriguez E, Miralles P, et al. Sustained virological response to interferon plus ribavirin reduces non-liver-related mortality in patients coinfected with HIV and Hepatitis C virus. Clin Infect Dis 2012;55(5):728-36
108. Laguno M, Martinez-Rebollar M, Perez I, et al. Low rate of sustained virological response in an outbreak of acute hepatitis C in HIV-infected patients. AIDS Res Hum Retroviruses 2012;28(10):1294-300
109. Vogel M, Dominguez S, Bhagani S, et al. Treatment of acute HCV infection in HIV-positive patients: experience from a multicentre European cohort. Antivir Ther 2010;15(2):267-79
110. Torriani FJ, Rodriguez-Torres M, Rockstroh JK, et al. Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med 2004;351(5):438-50
111. Neumann A, Polis M, Rozenberg L, et al. Differential antiviral effect of PEGinterferon- alpha-2b on HIV and HCV in the treatment of HIV/HCV co-infected patients. AIDS 2007;21(14):1855-65
112. Aguilar Marucco D, Veronese L, De Requena DG, et al. Antiretroviral activity of pegylated interferon alfa-2a in patients co-infected with HIV/hepatitis C virus. J Antimicrob Chemother 2007;59(3): 565-8
113. Investigators ST, Fidler S, Porter K, et al. Short-course antiretroviral therapy in primary HIV infection. N Engl J Med 2013;368(3):207-17
114. Thompson MA, Aberg JA, Hoy JF, et al. Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel. JAMA 2012;308(4):387-402
115. Williams I, Churchill D, Anderson J, et al. British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2012. HIV Med 2012;13(Suppl 2):1-85
116. Rodriguez-Novoa S, Morello J, Gonzalez M, et al. Increase in serum bilirubin in HIV/hepatitis-C virus-coinfected patients on atazanavir therapy following initiation of pegylated-interferon and ribavirin. AIDS 2008;22(18):2535-7
117. Hulskotte EG, Feng HP, Xuan F, et al. Pharmacokinetic interactions between the hepatitis C virus protease inhibitor boceprevir and ritonavir-boosted HIV-1 protease inhibitors atazanavir, darunavir, and lopinavir. Clin Infect Dis 2013;56(5): 718-26
118. Hammond KP, Wolfe P, Burton JR Jr, et al. Pharmacokinetic interaction between boceprevir and etravirine in HIV/HCV seronegative volunteers. J Acquir Immune Defic Syndr 2013;62(1):67-73
119. Garg V, Chandorkar G, Yang Y, et al. The effect of CYP3A inhibitors and inducers on the pharmacokinetics of telaprevir in healthy volunteers. Br J Clin Pharmacol 2013;75(2): 431-9
120. Mira JA, Lopez-Cortes LF, Barreiro P, et al. Efficacy of pegylated interferon plus ribavirin treatment in HIV/hepatitis C virus co-infected patients receiving abacavir plus lamivudine or tenofovir plus either lamivudine or emtricitabine as nucleoside analogue backbone. J Antimicrob Chemother 2008;62(6):1365-73
121. Solas C, Pambrun E, Winnock M, et al. Ribavirin and abacavir drug interaction in HIV-HCV coinfected patients: fact or fiction? AIDS 2012;26(17):2193-9
122. Cooper C, La Porte C, Tossonian H, et al. A pilot, prospective, open-label simplification study to evaluate the safety, efficacy, and pharmacokinetics of once-daily lopinavir-ritonavir monotherapy in HIV-HCV coinfected patients: the MONOCO study. HIV Clin Trials 2012; 13(4):179-88
123. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol 2011;55(2):245-64
124. Van Den Eynde E, Crespo M, Esteban JI, et al. Response-guided therapy for chronic hepatitis C virus infection in patients coinfected with HIV: a pilot trial. Clin Infect Dis 2009;48(8):1152-9
125. Sulkowski MS. Viral hepatitis and HIV coinfection. J Hepatol 2008;48(2):353-67
126. Labarga P, Barreiro P, Da Silva A, et al. Comparison of high ribavirin induction versus standard ribavirin dosing, plus peginterferon-alpha for the treatment of chronic hepatitis C in HIV-infected patients: the PERICO trial. J Infect Dis 2012;206(6):961-8
127. Sulkowski MS, Sherman KE, Dieterich DT, et al. Combination therapy with telaprevir for chronic hepatitis C virus genotype 1 infection in patients with HIV. A randomized trial. Ann Intern Med 2013; 159(2):86-96.
128. Sulkowski M, Pol S, Mallolas J, et al. Boceprevir versus placebo with pegylated interferon alfa-2b and ribavirin for treatment of hepatitis C virus genotype 1 in patients with HIV. A randomised, double-blind, controlled phase 2 trial. Lancet Infect Dis 2013;13(7):597-605.
129. Cotte L, Braun J, Lascoux-Combe C, et al. High early virological response with telaprevir-pegylated-interferon-ribavirin in treatment-experienced hepatitis C virus genotype 1/HIV co-infected patients: ANRS HC26 TelapreVIH Study. Presented at: 20th Conference on Retroviruses and Opportunistic Infections (CROI 2013); 3 - 6 March 2013; Atlanta, GA, USA
130. Deterding K, Gruner N, Buggisch P, et al. Delayed versus immediate treatment for patients with acute hepatitis C: a randomised controlled non-inferiority trial. Lancet Infect Dis 2013;13(6):497-506
131. European Aids Treatment Network Acute Hepatitis C Infection Consensus Panel. Acute hepatitis C in HIV-infected individuals: recommendations from the European AIDS Treatment Network (NEAT) consensus conference. AIDS 2011; 25(4):399-409
132. Laguno M, Murillas J, Blanco JL, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for treatment of HIV/HCV co-infected patients. AIDS 2004;18(13): F27-36
133. Martin-Carbonero L, Nunez M, Marino A, et al. Undetectable hepatitis C virus RNA at week 4 as predictor of sustained virological response in HIV patients with chronic hepatitis C. AIDS 2008;22(1):15-21
134. Dore GJ, Torriani FJ, Rodriguez-Torres M, et al. Baseline factors prognostic of sustained virological response in patients with HIV-hepatitis C virus co-infection. AIDS 2007;21(12):1555-9
135. Dayyeh BK, Gupta N, Sherman KE, et al. Aids Clinical Trials Group A5178 Study Team. IL28B alleles exert an additive dose effect when applied to HCV-HIV coinfected persons undergoing peginterferon and ribavirin therapy. PLoS ONE 2011; 6(10):e25753
136. Aparicio E, Parera M, Franco S, et al. IL28B SNP rs8099917 is strongly associated with pegylated interferon-alpha and ribavirin therapy treatment failure in HCV/HIV-1 coinfected patients. PLoS ONE 2010;5(10): e13771
137. Rallon NI, Lopez-Fernandez LA, Garcia MI, et al. Interferon-stimulated genes are associated with peginterferon/ribavirin treatment response regardless of IL28B alleles in hepatitis C virus/HIV-coinfected patients. AIDS 2013;27(5):687-96
138. Grebely J, Hellard M, Applegate T, et al. Virological responses during treatment for recent hepatitis C virus: potential benefit for ribavirin use in HCV/HIV co-infection. AIDS 2012;26(13):1653-61
139. Suppiah V, Moldovan M, Ahlenstiel G, et al. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet 2009;41(10): 1100-4
140. Payer BA, Reiberger T, Aberle J, et al. IL28B and interferon-gamma inducible protein 10 for prediction of rapid virologic response and sustained virologic response in HIV-HCV-coinfected patients. Eur J Clin Invest 2012;42(6):599-606
141. De Araujo ES, Dahari H, Cotler SJ, et al. Pharmacodynamics of PEG-IFN-[alpha]-2a and HCV response as a function of IL28B polymorphism in HIV/HCV-coinfected patients. J Acquir Immune Defic Syndr 2011;56(2):95-9
142. Jimenez-Sousa MA, Berenguer J, Rallon N, et al. IL28RA polymorphism is associated with early hepatitis C virus (HCV) treatment failure in human immunodeficiency virus-/HCV-coinfected patients. J Viral Hepat 2013;20(5):358-66
143. Rivero-Juarez A, Camacho A, Caruz A, et al. LDLr genotype modifies the impact of IL28B on HCV viral kinetics after the first weeks of treatment with PEG-IFN/RBV in HIV/HCV patients. AIDS 2012;26(8): 1009-15
144. Neukam K, Camacho A, Caruz A, et al. Prediction of response to pegylated interferon plus ribavirin in HIV/hepatitis C virus (HCV)-coinfected patients using HCV genotype, IL28B variations, and HCV-RNA load. J Hepatol 2012;56(4): 788-94
145. Nattermann J, Vogel M, Nischalke HD, et al. Genetic variation in IL28B and treatment-induced clearance of hepatitis C virus in HIV-positive patients with acute and chronic hepatitis C. J Infect Dis 2011; 203(5):595-601
146. Poordad F, Mccone J Jr, Bacon BR, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011; 364(13):1195-206
147. Dieterich D, Rockstroh J, Orkin C, et al. Simeprevir with Pegylated Interferon/Ribavirin in Patients Co-infected with Chronic Hepatitis C Virus and HIV-1: Week-24 Interim Analysis of the TMC435-C212 Study. Presented at: 20th Conference on Retroviruses and Opportunistic Infections (CROI 2013); 3 - 6 March 2013; Atlanta, GA, USA
148. Dieterich D, Soriano V, Nelson M, et al. STARTVerso 4. High rates of early virologic response in hepatitis C virus genotype 1/HIV co-infected patients treated with faldaprevir + pegylated interferon and ribavirin. Presented at: 20th Conference on Retroviruses and Opportunistic Infections (CROI 2013); 3 - 6 March 2013; Atlanta, GA, USA
149. Jacobson IM, Gordon SC, Kowdley KV, et al. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med 2013; 368(20):1867-77
150. Aghemo A, De Francesco R. New horizons in hepatitis C antiviral therapy with direct-acting antivirals. Hepatology 2013; 58(1):428-38
151. Sherman KE, Flamm SL, Afdhal NH, et al. Response-guided telaprevir combination treatment for hepatitis C virus infection. N Engl J Med 2011;365(11):1014-24
152. Benito JM, Sanchez-Parra C, Maida I, et al. Triple combination therapy for hepatitis C with telaprevir exhibits greater early antiviral activity than with boceprevir. Antivir Ther 2013;18(5):709-15
153. Susser S, Vermehren J, Forestier N, et al. Analysis of long-term persistence of resistance mutations within the hepatitis C virus NS3 protease after treatment with telaprevir or boceprevir. J Clin Virol 2011; 52(4):321-7
154. Romano KP, Ali A, Aydin C, et al. The molecular basis of drug resistance against hepatitis C virus NS3/4A protease inhibitors. PLoS Pathog 2012;8(7): e1002832
155. Lam AM, Espiritu C, Bansal S, et al. Genotype and subtype profiling of PSI-7977 as a nucleotide inhibitor of hepatitis C virus. Antimicrob Agents Chemother 2012;56(6):3359-68
156. Kowdley KV, Lawitz E, Crespo I, et al. Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, multicentre phase 2 trial. Lancet 2013; 381(9883):2100-7
157. Sulkowski MS, Gardiner DF, Rodriguez-Torres M, et al. Sustained virologic response with daclatasvir plus sofosbuvir ± ribavirin (RBV) in chronic HCV genotype (GT) 1-infected patients who previously failed telaprevir (TVR) or boceprevir (BOC). Presented at: 48th Annual Meeting of the European Association for the Study of the Liver (EASL 2013); 24 - 28 April 2013; Amsterdam, Netherlands
158. Pelosi LA, Voss S, Liu M, et al. Effect on hepatitis C virus replication of combinations of direct-acting antivirals, including NS5A inhibitor daclatasvir. Antimicrob Agents Chemother 2012;56(10):5230-9
159. Fierer D. Telaprevir for acute hepatitis C virus in HIV+ men both shortens treatment and improves outcome. Presented at: 20th Conference on Retroviruses and Opportunistic Infections (CROI 2013); 3 - 6 March 2013; Atlanta, GA, USA
160. Terrault NA, Roland ME, Schiano T, et al. Outcomes of liver transplant recipients with hepatitis C and human immunodeficiency virus co-infection. Liver Transpl 2012;18(6): 716-26 .
161. Kemmer NM, Sherman KE. Liver transplantation trends in the HIV population. Dig Dis Sci 2011;56(11): 3393-8
162. Anadol E, Beckebaum S, Radecke K, et al. Orthotopic liver transplantation in humanimmunodeficiency- virus-positive patients in Germany. AIDS Res Treat 2012;2012:197501
163. Miro JM, Montejo M, Castells L, et al. Outcome of HCV/HIV-coinfected liver transplant recipients: a prospective and multicenter cohort study. Am J Transplant 2012;12(7):1866-76.
164. Gutierrez-Moreno M, Bernal-Bellido C, Suarez-Artacho G, et al. Spontaneous clearance of HCV in HIV-Hepatitis C virus coinfected liver transplant patients: prospective study. Transplant Proc 2012; 44(7):2100-2
165. Samri A, Roque-Afonso AM, Beran O, et al. Preservation of immune function and anti-hepatitis C virus (HCV) immune responses after liver transplantation in HIV-HCV coinfected patients (ANRSHC08 "THEVIC" trial). J Hepatol 2009; 51(6):1000-9
166. Fontana RJ, Hughes EA, Bifano M, et al. Sofosbuvir and daclatasvir combination therapy in a liver transplant recipient with severe recurrent cholestatic hepatitis C. Am J Transplant 2013;13(6):1601-5
167. Baccarani U, Adani GL, Bragantini F, et al. Long-term outcomes of orthotopic liver transplantation in human immunodeficiency virus-infected patients and comparison with human immunodeficiency virus-negative cases. Transplant Proc 2011;43(4):1119-22
168. Bahirwani R, Barin B, Olthoff K, et al. Chronic kidney disease after liver transplantation in human immunodeficiency virus/hepatitis C virus-coinfected recipients versus human immunodeficiency virus-infected recipients without hepatitis C virus: results from the national institutes of health multi-site study. Liver Transpl 2013; 19(6):619-26